Seminars in interventional cardiology : SIIC最新文献

Transmyocardial revascularization (TMR) using holmium:yttrium-aluminium-garnet (YAG) and carbon dioxide lasers has been approved by the United States Food and Drug Administration for the treatment of medically refractory angina in patients without conventional options. In prospective, randomized trials, patients who received TMR experienced improved angina, better-event free survival, and reduction in cardiac-related rehospitalizations when compared to patients remaining on medical therapy alone. In addition, TMR as an adjunct to coronary artery bypass grafting (CABG) has resulted in improved clinical status for patients who would not be completely revascularized by CABG alone.

Direct myocardial revascularization (DMR) has been proposed to treat patients with severe coronary artery disease who are not amenable for classical revascularization techniques such as percutaneous coronary intervention (PCI) or bypass surgery (CABG). Although recent reports suggest its benefit in alleviating patients' complaints in the long term, there is still a paucity of data on the immediate impact on regional and global myocardial functioning following this treatment. In this overview we discuss our own experience and provide a summary of other data currently available.

The standard technique for the treatment of descending thoracic aortic aneurysms is elective open surgical repair with graft interposition. This standard approach, although steadily improving, is associated with high morbidity and substantial mortality rates and implies a major surgical procedure with lateral thoracotomy, use of cardiopulmonary bypass, long operation times and a variety of peri- and postoperative complications. This and the success of the first endoluminal treatment of abdominal aortic aneurysms by Parodi et al. prompted the attention to be thrown on the treatment of descending thoracic aortic aneurysms with endoluminal stent-grafts in many large centres. The aim of this new minimally invasive technique is to exclude the aneurysm from blood flow and in consequence to avoid pressure stress on the aneurysmatic aortic wall, by avoiding a large open operation with significant perioperative morbidity. The potentially beneficial effect of this new treatment approach was evaluated in the course of this study.

EUROSTAR (EUROpean collaborators on Stent-graft Techniques for abdominal aortic Aneurysm Repair) was established for the purpose of combining and studying data on endovascular abdominal aortic aneurysm (AAA) repair. EUROSTAR is independent of any commercial interest, and aims to provide scientifically reliable assessment of endovascular AAA grafting. The results of 2,016 patients from 98 European institutions have been collected and analysed. Despite the minimally invasive nature of endovascular aneurysm repair, a variety of complications do occur with considerable frequency. Complications are more often encountered in patients with large aneurysms, advanced age, and if adjuvant procedures are required. In addition, a compromised cardiac and general medical status has adverse effects on the risk of systemic complications. The experience of the operating team is an important factor, influencing device- and procedure-related complications. The observed 18-month endoleak-free survival reflects a satisfactory mid-term result.

The endovascular treatment of abdominal aortic aneurysms (AAAs) is rapidly evolving. Since the onset of clinical investigations in 1990 there has been a rapid proliferation in the number of available devices, both surgeon-made and industry-made. This chapter reviews endovascular AAA repair with regard to available devices, patient selection for each device based on anatomic criteria, and techniques for graft deployment.